<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005046.pub3" GROUP_ID="UPPERGI" ID="186403102212004692" MERGED_FROM="" MODIFIED="2014-11-17 14:55:54 +0000" MODIFIED_BY="Karin Dearness" NOTES="&lt;p&gt;Converted to RM5 by CB 16/10/2008&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 10:35:21 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="12" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2014-11-17 14:55:54 +0000" MODIFIED_BY="Karin Dearness">
<TITLE>Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia</TITLE>
<CONTACT MODIFIED="2014-11-17 14:55:54 +0000" MODIFIED_BY="Karin Dearness"><PERSON ID="19849" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Leyden</LAST_NAME><POSITION>Consultant Gastroenterologist</POSITION><EMAIL_1>janleyden@eircom.net</EMAIL_1><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>Mater Misericordiae University Hospital</ORGANISATION><ADDRESS_1>Eccles Street</ADDRESS_1><CITY>Dublin</CITY><ZIP>Dublin 7</ZIP><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 8032940</PHONE_1><FAX_1>+353 1 8034770</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-11-17 14:55:54 +0000" MODIFIED_BY="Karin Dearness"><PERSON ID="19849" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Leyden</LAST_NAME><POSITION>Consultant Gastroenterologist</POSITION><EMAIL_1>janleyden@eircom.net</EMAIL_1><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>Mater Misericordiae University Hospital</ORGANISATION><ADDRESS_1>Eccles Street</ADDRESS_1><CITY>Dublin</CITY><ZIP>Dublin 7</ZIP><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 8032940</PHONE_1><FAX_1>+353 1 8034770</FAX_1></ADDRESS></PERSON><PERSON ID="16694" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Moss</LAST_NAME><POSITION>Director of Translational Research</POSITION><EMAIL_1>amoss@bidmc.harvard.edu</EMAIL_1><ADDRESS><DEPARTMENT>Center for Inflammatory Bowel Disease</DEPARTMENT><ORGANISATION>Beth Israel Deaconess Medical Center</ORGANISATION><ADDRESS_1>Rabb/Rose 1, East</ADDRESS_1><ADDRESS_2>Brookline Ave</ADDRESS_2><CITY>Boston</CITY><ZIP>02215</ZIP><REGION>MA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 617 6671088</PHONE_1><FAX_1>+1 617 6671181</FAX_1></ADDRESS></PERSON><PERSON ID="19851" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Padraic</FIRST_NAME><LAST_NAME>MacMathuna</LAST_NAME><SUFFIX>MD FRCPI</SUFFIX><POSITION>Associate Professor of Medicine</POSITION><EMAIL_1>pmacmathuna@mater.ie</EMAIL_1><ADDRESS><ORGANISATION>Mater Misericordiae University Hospital</ORGANISATION><ADDRESS_1>Eccles Street</ADDRESS_1><CITY>Dublin</CITY><ZIP>Dublin 7</ZIP><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 8032366</PHONE_1><FAX_1>+353 1 8034770</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-08-21 14:18:16 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-08-21 14:19:12 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-08-21 14:19:00 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2014"/>
<DESCRIPTION>
<P>One new RCT identified and included in meta-analysis. Conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-08-21 14:19:12 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Searches rerun and review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-07-14 10:05:52 -0400" MODIFIED_BY="Karin Dearness">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-07-14 10:05:52 -0400" MODIFIED_BY="Karin Dearness">
<DATE DAY="5" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-05 09:55:26 -0400" MODIFIED_BY="Karin Dearness">
<DATE DAY="2" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Revision to the risk of bias characteristic of included studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-07-02 14:51:23 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="2" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Review updated. No new studies. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-01 23:02:47 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-05-13 09:51:16 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-16 09:28:41 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="29" MONTH="10" YEAR="2005"/>
<DESCRIPTION>
<P>New studies found and included or excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-16 09:28:44 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="18" MONTH="10" YEAR="2005"/>
<DESCRIPTION>
<P>New studies sought but none found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-16 09:28:48 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="1" MONTH="10" YEAR="2005"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-11-04 10:35:21 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-11-04 10:35:21 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-11-04 10:35:21 -0500" MODIFIED_BY="[Empty name]">
<NAME>Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Upper GI and Pancreatic Cochrane Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-04 01:15:41 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-11-03 23:27:10 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-11-03 22:08:53 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Title edited&lt;/p&gt;" NOTES_MODIFIED="2014-11-03 22:08:53 -0500" NOTES_MODIFIED_BY="[Empty name]">Endoscopic balloon dilation versus botulinum toxin (Botox) injection for managing achalasia, a condition causing difficulty in swallowing
</TITLE>
<SUMMARY_BODY MODIFIED="2014-11-03 23:27:10 -0500" MODIFIED_BY="[Empty name]">
<P>Achalasia is an oesophageal motility disorder which results in increased lower oesophageal sphincter (LOS) tone and symptoms of difficulty swallowing. Treatments are aimed at reducing the tone of the LOS and include the endoscopic options of pneumatic dilation (PD) or local botulinum toxin (BTX) injection. We set out to undertake a systematic review comparing randomised controlled trials that examined the efficacy and safety of PD and BTX injection in people
 with achalasia. We searched databases (MEDLINE, EMBASE, ISI Web of Science, and The Cochrane Library) in April
 2014 for reports of relevant randomised controlled trials. Seven randomised controlled trials were identified for inclusion in the review, and five were suitable for meta-analysis. Meta-analysis suggested that, although both interventions had similar initial response rates, the remission rates at six and 12 months were significantly greater with PD than with BTX injection.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-11-03 23:26:28 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-11-03 21:45:19 -0500" MODIFIED_BY="[Empty name]">
<P>Achalasia is an oesophageal motility disorder, of unknown cause, which results in increased lower oesophageal sphincter (LOS) tone and symptoms of difficulty swallowing. Treatments are aimed at reducing the LOS tone. Current endoscopic therapeutic options include pneumatic dilation (PD) or botulinum toxin (BTX) injection.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-11-03 23:11:25 -0500" MODIFIED_BY="[Empty name]">
<P>To undertake a systematic review comparing the efficacy and safety of two endoscopic treatments, PD and intrasphincteric BTX injection, in the treatment of oesophageal achalasia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-11-03 23:26:28 -0500" MODIFIED_BY="[Empty name]">
<P>Trials were initially identified by searching MEDLINE (1966 to August 2008), EMBASE (1980 to September 2008), ISI Web of Science (1955 to September 2008), The Cochrane Library Issue 3, 2008.  Searches in all databases were conducted in October 2005 and updated in September 2008 and April 2014. The Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE, sensitivity maximising version in the Ovid format, was combined with specific search terms to identify randomised controlled trials in MEDLINE. The MEDLINE search strategy was adapted for use in the other databases that were searched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-11-03 21:54:44 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing PD to BTX injection in individuals with primary achalasia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-11-03 21:54:54 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed study quality assessment and data extraction.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-11-03 22:01:37 -0500" MODIFIED_BY="[Empty name]">
<P>Seven studies involving 178 participants were included. Two studies were excluded from the meta-analysis of remission rates on the basis of clinical heterogeneity of the initial endoscopic protocols. There was no significant difference between PD or BTX treatment in remission within four weeks of the initial intervention; with a risk ratio of remission of 1.11 (95% CI 0.97 to 1.27). There was also no significant difference in the mean oesophageal pressures between the treatment groups; with a weighted mean difference for PD of -0.77 (95% CI -2.44 to 0.91, P = 0.37). Data on remission rates following the initial endoscopic treatment were available for three studies at six months and four studies at 12 months. At six months 46 of 57 PD participants were in remission compared to 29 of 56 in the BTX group, giving a risk ratio of 1.57 (95% CI 1.19 to 2.08, P = 0.0015); whilst at 12 months 55 of 75 PD participants were in remission compared to 27 of 72 BTX participants, with a risk ratio of 1.88 (95% CI 1.35 to 2.61, P = 0.0002). No serious adverse outcomes occurred in participants receiving BTX, whilst PD was complicated by perforation in three cases.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-03 22:02:05 -0500" MODIFIED_BY="[Empty name]">
<P>The results of this meta-analysis suggest that PD is the more effective endoscopic treatment in the long term (greater than six months) for patients with achalasia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-04 01:14:06 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-11-03 23:07:18 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-11-03 22:52:02 -0500" MODIFIED_BY="[Empty name]">
<P>Achalasia is an oesophageal motility disorder of unknown cause that manifests as symptoms of difficulty swallowing (dysphagia), with pooling of food and secretions in the lower oesophagus. The annual incidence has been estimated at approximately 1:100,000 (<LINK REF="REF-Mayberry-1987" TYPE="REFERENCE">Mayberry 1987</LINK>; <LINK REF="REF-Howard-1992" TYPE="REFERENCE">Howard 1992</LINK>). The onset of symptoms is often insidious, usually between the ages of 25 and 60 years, and symptoms gradually progress over a period of years (<LINK REF="REF-Eckardt-1997" TYPE="REFERENCE">Eckardt 1997</LINK>).</P>
<P>The condition is characterised by degeneration of ganglion cells, predominantly the inhibitory neurons in the myenteric plexus of the lower oesophageal sphincter (LOS). This leads to a rise in the basal tone of the sphincter, loss of peristalsis in the distal oesophagus, and a lack of coordinated LOS relaxation in response to swallowing. Achalasia may be suspected from the clinical history, however radiographic, endoscopic, and, most importantly, manometric assessment are need to confirm the diagnosis (<LINK REF="REF-Reynolds-1989" TYPE="REFERENCE">Reynolds 1989</LINK>).</P>
<P>The function of the degenerated myenteric plexus neurons cannot be restored, therefore treatments are aimed at reducing the tone of the LOS. These include pharmacological therapy, surgical myotomy, and endoscopic pneumatic dilation (PD) or intrasphincteric botulinum toxin (BTX) injection. Pharmacological treatments such as oral nitrates, calcium channel blockers, anticholinergic agents, and beta-adrenergic agonists have proven disappointing to date (<LINK REF="REF-Bassotti-1999" TYPE="REFERENCE">Bassotti 1999</LINK>; <LINK REF="REF-Wen-2004" TYPE="REFERENCE">Wen 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-11-03 23:04:22 -0500" MODIFIED_BY="[Empty name]">
<P>Surgical myotomy (Heller's myotomy) is an effective treatment option with good long-term results. Whilst laparoscopic Heller's myotomy is generally accepted as the operative procedure of choice, endoscopic therapy remains a valid option in the primary management of achalasia (<LINK REF="REF-Urbach-2001" TYPE="REFERENCE">Urbach 2001</LINK>; <LINK REF="REF-Frantzides-2004" TYPE="REFERENCE">Frantzides 2004</LINK>; <LINK REF="REF-Vela-2004" TYPE="REFERENCE">Vela 2004</LINK>).</P>
<P>Standard endoscopic therapeutic options include PD or BTX injection. A variety of balloon types and protocols have been used to treat this condition, with reported long-term efficacy of up to 90%. The major complication associated with PD is oesophageal perforation, which occurs in up to 3% of cases (<LINK REF="REF-Katz-1998" TYPE="REFERENCE">Katz 1998</LINK>; <LINK REF="REF-Kadakia-2001" TYPE="REFERENCE">Kadakia 2001</LINK>). PD appears to be the least costly treatment (<LINK REF="REF-Imperiale-2000" TYPE="REFERENCE">Imperiale 2000</LINK>). Recently, a novel endoscopic myotomy procedure, peroral endoscopic myotomy (POEM), has been developed which has shown similar short-term outcomes to Heller's myotomy (<LINK REF="REF-Pasricha-2007" TYPE="REFERENCE">Pasricha 2007</LINK>; <LINK REF="REF-Inoue-2010" TYPE="REFERENCE">Inoue 2010</LINK>; <LINK REF="REF-Von-Renteln-2013" TYPE="REFERENCE">Von Renteln 2013</LINK>). POEM is a complex endoscopic procedure which is only performed in specialist centres.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-11-03 23:07:18 -0500" MODIFIED_BY="[Empty name]">
<P>Intrasphincteric injection of BTX is an alternative endoscopic therapy to PD (<LINK REF="REF-Pasricha-1994" TYPE="REFERENCE">Pasricha 1994</LINK>; <LINK REF="REF-Pasricha-1995" TYPE="REFERENCE">Pasricha 1995</LINK>). It is a safe procedure, being associated with few side effects or complications (<LINK REF="REF-Cuilliere-1997" TYPE="REFERENCE">Cuilliere 1997</LINK>). Usually 80 to 100 units of BTX are injected with a sclerotherapy needle in divided doses into the four quadrants of the LOS, under direct vision. Although an efficacy of about 85% in the short-term period has been reported, this decreases to 50% at six months and 30% after one year (<LINK REF="REF-Annese-1998" TYPE="REFERENCE">Annese 1998</LINK>; <LINK REF="REF-Bassotti-1999" TYPE="REFERENCE">Bassotti 1999</LINK>; <LINK REF="REF-Kolbasnik-1999" TYPE="REFERENCE">Kolbasnik 1999</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-11-03 23:12:32 -0500" MODIFIED_BY="[Empty name]">
<P>To undertake a systematic review comparing the efficacy and safety of two endoscopic treatments, intrasphincteric botulinum toxin (BTX) injection and pneumatic dilation (PD), in the treatment of oesophageal achalasia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-03 23:45:45 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-11-03 23:36:37 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-11-03 23:13:22 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials, with or without blinding, comparing endoscopic intrasphincteric BTX injection to endoscopic PD in the treatment of achalasia.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-11-03 23:14:41 -0500" MODIFIED_BY="[Empty name]">
<P>Individuals of any age diagnosed with achalasia by a combination of clinical, endoscopic, radiographic, or manometric investigations, including patients who had received previous endoscopic treatments.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-11-03 23:16:30 -0500" MODIFIED_BY="[Empty name]">
<P>The following interventions were compared in the treatment of achalasia:<BR/>
</P>
<UL>
<LI>endoscopic BTX injection;</LI>
<LI>endoscopic PD.</LI>
</UL>
<P>Varying doses and frequencies of BTX, and different types of balloon and methods of PD were considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-11-03 23:36:37 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-11-03 23:18:12 -0500" MODIFIED_BY="[Empty name]">
<P>Symptom remission rates within the first month, at six months, and at 12 months</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-11-03 23:36:37 -0500" MODIFIED_BY="[Empty name]">
<P>Lower oesophageal sphincter (LOS) pressure confirmed by oesophageal manometry post-treatment</P>
<P>Complications directly related to the endoscopic therapy</P>
<P>Quality of life post-intervention</P>
<P>Cost-effectiveness</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-11-03 23:27:33 -0500" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-11-03 23:27:33 -0500" MODIFIED_BY="[Empty name]">
<P>Searches were conducted to identify all published and unpublished randomised controlled trials. Articles published in any language were included. Trials were identified by searching MEDLINE (1946 to week 3 March 2014), EMBASE (1980 to week 12 2014), ISI Web of Science (1955 to March 2014), Cochrane Central Register of Controlled Trials<B> (</B>January 2014). Searches in all databases were conducted initially in October 2005 and updated in September 2008, July 2011, and April 2014. The Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE, sensitivity maximising version in the Ovid format (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>), was combined with the search terms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to identify randomised controlled trials in MEDLINE. The MEDLINE search strategy was adapted for use in the other databases that were searched for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-11-03 23:24:50 -0500" MODIFIED_BY="[Empty name]">
<P>Reference lists from trials selected by electronic searching were handsearched to identify further relevant trials. Published abstracts from conference proceedings in the United European Gastroenterology Week (published in Gut) and Digestive Disease Week (published in Gastroenterology) were handsearched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-03 23:45:45 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-11-03 23:30:45 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently scanned the abstract of each trial identified by the search to determine eligibility. The authors were not blinded to the sources of the trials. We selected full articles for further assessment if the abstract suggested the study was a randomised controlled trial of patients with achalasia comparing balloon dilation to BTX injection. If these criteria were unclear from the abstract, the full article was retrieved for clarification. Studies meeting the inclusion criteria were included for review and data extraction. Papers not meeting the inclusion criteria were excluded. Any disagreements were resolved by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-11-03 23:37:39 -0500" MODIFIED_BY="[Empty name]">
<P>We extracted data from published reports using predetermined standardised forms. Disagreements were resolved by discussion between the review authors. The following data were extracted wherever possible:</P>
<UL>
<LI>method of randomisation;</LI>
<LI>blinding for outcome assessor, patient, and carer;</LI>
<LI>criteria for patient inclusion and exclusion;</LI>
<LI>history of previous treatment for achalasia;</LI>
<LI>participants' characteristics including mean or median age, age range, sex ratio;</LI>
<LI>number of participants assigned to each treatment group;</LI>
<LI>number of co-morbid conditions, with details of intervention;</LI>
<LI>type of intervention per endoscopic session, type of balloon and pressures attained;</LI>
<LI>effect on symptoms;</LI>
<LI>effect on LOS pressure;</LI>
<LI>effect on quality of life;</LI>
<LI>number and frequency of procedure related complications;</LI>
<LI>duration of therapy and any co-interventions;</LI>
<LI>frequency of re-interventions;</LI>
<LI>number of participants withdrawn and reasons for these withdrawals;</LI>
<LI>adverse reactions and outcomes.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-11-03 23:41:00 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Quality assessment of trials</HEADING>
<P>Two review authors independently assessed the methodological quality of the selected trials using the following criteria:</P>
<OL>
<LI>the method of randomisation;</LI>
<LI>allocation concealment;</LI>
<LI>baseline comparability of study groups;</LI>
<LI>blinding and completeness of follow up.</LI>
</OL>
<P>We did not use blinding of participants or intervention providers as an assessment criterion given the nature of the interventions being studied. Trials were graded: A - adequate, B - unclear, C - inadequate on each criterion and thus each randomised controlled trial (RCT) was graded as having low, moderate, or high risk of bias. If it was unclear whether a criterion had been met, we sought further information from the author. Any disagreements were resolved by discussion.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-11-03 23:45:45 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Statistical analyses</HEADING>
<P>Statistical guidance was available from the editorial base and the review authors' host institutions. The variation in type of balloon used and pressures attained at dilation, the dose of BTX injected, and the history of previous endoscopic treatment were considered as potential causes of heterogeneity. Dichotomous data were summarised using the risk ratio and reported with 95% confidence intervals. The relative risk of remission was calculated at each of the three time points. Continuous data were summarised using weighted mean difference and reported with 95% confidence intervals.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-04 01:10:53 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-11-04 00:08:47 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-11-03 23:46:34 -0500" MODIFIED_BY="[Empty name]">
<P>We identified studies using the search criteria and assessed nine full-text articles for eligibility, as shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-11-04 00:07:08 -0500" MODIFIED_BY="[Empty name]">
<P>The seven included studies were RCTs involving patients with a diagnosis of primary achalasia based on clinical, endoscopic, manometric, and radiographic criteria. Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Treatments</HEADING>
<UL>
<LI>A 30 mm diameter PD balloon was used in five studies (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>; <LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>; <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>). In one of these PD was performed on three consecutive days (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>), with a 35 mm balloon being used on the second and third day. The total BTX dose administered varied from 60 to 100 units in these five studies.</LI>
</UL>
<UL>
<LI>The two remaining studies compared a 40 mm balloon either as a single PD session (<LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>) or two sessions one day apart (<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>) to a total BTX dose of 80 U.</LI>
</UL>
<UL>
<LI>In one study participants not responding to the initial BTX injection received a further injection one week later (<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>).</LI>
</UL>
<UL>
<LI>Some participants who either failed to respond to the initial endoscopic treatment or who relapsed during the study period underwent a repeat procedure or were crossed over to the alternative treatment in all six studies.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<UL>
<LI>Changes in achalasia symptoms and LOS pressure in response to both treatments were assessed between one and four weeks after the initial treatment in all studies. The methods used for scoring achalasia symptoms varied between studies; however, most defined remission as 50% or greater improvement in the symptom score. The symptom scores were further assessed in all studies, and LOS pressure in three of the studies, over a 12 month period (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>; <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>). Data on the response to the initial endoscopic treatment only, at six and 12 months, were available in five of the studies (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>; <LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>; <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>).</LI>
</UL>
<UL>
<LI>All studies compared cumulative remission over a 12 month period, however the definition of remission varied between studies. Remission was defined as a 50% or greater reduction in symptoms in three studies (<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>; <LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>). A further study (<LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>) calculated a total symptom score derived from the combination of the symptoms of dysphagia, chest pain, and regurgitation, each given a score of 0 to 3. This score was then divided into four grades (0 to 3), defined as symptom scores of 0 to 1, 2 to 3, 4 to 6, and &gt; 6 respectively. Remission was defined as a symptom score reduction of &gt; 1 grade, with a sustained response. Remission was not specifically defined in the study by Ghoshal (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>) but all responders experienced at least a 50% reduction in symptoms. Annese (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>) calculated a similar symptom score (0 to 9) and defined remission as a score of &lt; 2. Zhu (<LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>) calculated a total symptom score derived from the combination of the symptoms of solid and liquid dysphagia, active and passive regurgitation, and chest pain. The severity of each of these symptoms was scored on a scale of 0 to 3, thus the highest obtainable score was 15. A symptom score &lt; 4 was deemed a clinical response. Only two studies used Kaplan-Meier survival analysis to assess remission rates after a single endoscopic treatment (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>).</LI>
</UL>
<UL>
<LI>Quality of life and cost-effectiveness were not measured in any of the included studies.</LI>
</UL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-11-04 00:08:47 -0500" MODIFIED_BY="[Empty name]">
<P>We excluded 10 studies from the analysis (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). One full-text paper (<LINK REF="STD-Allescher-2001" TYPE="STUDY">Allescher 2001</LINK>) and one meeting abstract (<LINK REF="STD-Jung-2012" TYPE="STUDY">Jung 2012</LINK>) reported non-randomised studies. Three studies, published as meeting abstracts, were preliminary results of included studies (<LINK REF="STD-Bansal-1996" TYPE="STUDY">Bansal 1996</LINK>; <LINK REF="STD-Muehldorfer-1998" TYPE="STUDY">Muehldorfer 1998</LINK>; <LINK REF="STD-Malekzadeh-2000" TYPE="STUDY">Malekzadeh 2000</LINK>). Four studies, published as meeting abstracts only, were excluded as we were unable to contact the authors to obtain additional information regarding the studies (<LINK REF="STD-Gaudric-1996" TYPE="STUDY">Gaudric 1996</LINK>; <LINK REF="STD-Nebendahl-1998" TYPE="STUDY">Nebendahl 1998</LINK>; <LINK REF="STD-des-Varannes-1999" TYPE="STUDY">des Varannes 1999</LINK>; <LINK REF="STD-Linghu-2013" TYPE="STUDY">Linghu 2013</LINK>). One study (<LINK REF="STD-Zhou-2012" TYPE="STUDY">Zhou 2012</LINK>) was not included as only the abstract was published in English and we were unable to contact the author to obtain additional information. Please see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-11-04 01:04:41 -0500" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2014-06-16 17:25:55 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Method of randomisation</HEADING>
<P>The method of randomisation was adequate in four studies (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>; <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>), and unclear in the remaining three (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>; <LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>; <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-11-04 01:04:41 -0500" MODIFIED_BY="[Empty name]">
<P>Two of the seven studies were double blind trials (<LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>). A further study reported blinding of those assessing LOS pressure (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>). In the studies by <LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>; <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; and <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK> the assessors were not blinded. The study by <LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK> had been classified as double blind in the original review but has been reclassified in this update. Blinding was unclear in the remaining study (<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-11-04 00:11:28 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Follow up</HEADING>
<P>A total of 11 out of 239 participants were excluded from the post-treatment analysis either due to loss to follow up or non-compliance with the study protocols. In one study five (11%) of the initially randomised patients were excluded from the post-treatment analysis (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>).</P>
</SUBSECTION>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2014-11-04 01:02:21 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparability of treatment groups</HEADING>
<P>The clinical characteristics of participants in both treatment groups were similar in all but one study: the BTX group were older in the study by <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>. Two studies included participants who had been unsuccessfully treated with PD in the past: eight of the PD group and seven of the BTX group in the study by <LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>; two of the BTX group in the study by <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-04 01:10:53 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Response to initial endoscopic treatment</HEADING>
<P>Five studies compared a single BTX injection to a single PD initially (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>; <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>). In the two remaining studies the initial PD treatment consisted of repeated dilatations within a period of three days and was compared to a single BTX injection (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>), or an initial injection and a subsequent injection one week later in non-responders (<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>). Due to this clinical heterogeneity in treatment protocols neither of these studies were included in this analysis.</P>
<P>Following the initial endoscopic therapy 82 out of 95 PD participants were in remission compared to 73 out of 94 BTX participants, with a risk ratio of remission of 1.11 (95% CI 0.97 to 1.27; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) for PD. This did not reach statistical significance (P = 0.12).</P>
<P>Four of the five studies reported mean oesophageal pressures within four weeks of the initial endoscopic treatment (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>). The remaining study reported median and interquartile scores; individual patient data were not available (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>). There was no significant difference in the mean oesophageal pressures between the treatment groups, with a weighted mean difference for PD of -0.79 (95% CI -2.29 to 0.71; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Sensitivity analysis was performed by altering the statistical test (odds ratio or risk difference) and model (random-effects or fixed-effect) and did not change the results. There was no statistical heterogeneity between the studies.</P>
<P>In the study by <LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK> eight participants were randomised to receive 100 U of BTX and eight to undergo PD. Two further PD sessions were performed on consecutive days. Remission was defined as a symptom score of 2 (range 0 to 9). All participants were in remission at one month. The mean LOS pressure was reduced by 73% (37 to 9.9 mm Hg) in the PD group and by 48% (34.1 to 17.6 mm Hg) in the BTX group at one month; this was not statistically significant (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In the study by <LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK> 12 participants were randomised to receive 80 U BTX and 12 to undergo PD. A further PD was performed two days later. Remission was defined as a 50% or greater improvement in the median symptom score (range 0 to 20). At one week 10 of 12 (83%) PD participants compared to 8 of 12 (67%) BTX participants were in remission (P = 0.64). A second injection achieved therapeutic success in one of 4 non-responders; thus, 9 of 12 BTX participants (75%) responded positively overall. Mean LOS pressure readings before and after treatment were assessed in 7 PD and 9 BTX participants. The mean LOS pressure was reduced by 50%, from 35 mm Hg to 17 mm Hg in the PD group (P &lt; 0.001). In the BTX group a 44% reduction was observed, 39 mm Hg to 22 mm Hg (P &lt; 0.001) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Remission at six months and 12 months</HEADING>
<P>Data on remission rates following both initial treatments were available for three studies (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>) at six months, and four studies at 12 months (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>; <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>; <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>). The six and 12 month remission rates in the study by <LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK> included participants who had undergone a second endoscopic treatment, therefore these data were not included in our analysis.</P>
<P>At six months 46 of 57 PD participants were in remission compared to 29 of 56 in the BTX group, giving a risk ratio of 1.57 (95% CI 1.19 to 2.08, P = 0.0015; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>); whilst at 12 months 55 of 75 PD participants were in remission compared to 27 of 72 BTX participants, with a risk ratio of 1.88 (95% CI 1.35 to 2.61, P = 0.0002; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Sensitivity analysis was performed by altering the statistical test (odds ratio or risk difference) and model (random-effects or fixed-effect) and did not change the results at the one and 12 month analysis of remission but did at the six month analysis. The risk ratio random-effects model in the six month analysis was 1.94 (95% CI 0.77 to 4.85, P = 0.16). There was evidence of statistical heterogeneity in the six month remission analysis (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The remission rates for BTX in the largest study (<LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>) were greater than the other two studies included in this analysis (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>).</P>
<P>In the study by <LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK> six of eight (80%) BTX patients were in remission at six months, while only one (12.5%) was in remission at 12 months. All of the PD patients remained in remission (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In the study by Muehldorfer 9 of 12 (75%) PD patients were in remission at six months compared to 6 of 12 (50%) BTX patients, whilst the numbers in remission at 12 months were 8 (66%) and 3 (25%) respectively (<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Complications</HEADING>
<P>A total of 188 PD procedures and 151 BTX injections were performed in the six studies, either as the initial treatment or as a subsequent treatment in those who failed to respond to the initial treatment (PD or BTX) or who relapsed. BTX injection was not associated with any serious complications. Three oesophageal perforations were reported following PD.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life and cost-effectiveness</HEADING>
<P>Quality of life and cost-effectiveness analyses were not performed in this review as they were not assessed in any of the selected studies.<B>
<BR/>
</B>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-11-04 00:58:36 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-11-04 00:58:36 -0500" MODIFIED_BY="[Empty name]">
<P>The initial PD protocols of two studies (<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>; <LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>) involved repeated dilation over a short period, whilst the remaining five studies initially compared a single PD session to a single BTX injection. This was felt by both of the study authors to be clinically relevant but precluded these studies from inclusion in the meta-analysis (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Ideally Kaplan-Meier plots and log-rank testing should be used to compare duration of remission, however only two studies used this approach to compare remission rates after a single endoscopic treatment (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>; <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>).</P>
<P>There was no significant difference in remission within the first four weeks. Remission rates were greater at both six and 12 months for PD compared to BTX (PD rate approximately double the rate for BTX at 12 months), however two of the four studies were excluded from the six month analysis (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>; <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>) and one from the 12 month analysis (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>) due to incomplete data. Data on the remission rate at six months following BTX injection were not clear in the study by <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>. We were unable to contact the corresponding author for more information. In the study by Vaezi a second endoscopic treatment was performed in participants who relapsed during the study period and these participants were included in the outcomes analysis at six and 12 months (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>). It was not possible to obtain data from the corresponding author of this study on the outcomes at six and 12 months for participants who did not receive a second endoscopic treatment. It is unlikely that the missing data would significantly alter the outcome of this meta-analysis. The differences in outcomes highlighted in this analysis could be due to differences in the number of studies and of participants included at the various time points.</P>
<P>A comparison of the effect of either treatment on achalasia symptoms was not possible due to inter-study variation in the scoring of symptoms, therefore we looked at remission rates at the various time points. Remission was defined as a 50% or greater reduction in symptoms in the studies by <LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK> and <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK>. Remission in the study by <LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK> equated to a 50% or greater reduction in symptoms, whilst in the study by <LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK> remission was approximately equivalent to a 50% reduction in achalasia symptoms (individual patient data were not available). <LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK> calculated a total symptom score derived from symptoms of solid and liquid dysphagia, active and passive regurgitation, and chest pain; each scored on a scale of 0 to 3. A symptom score &lt; 4 was deemed a clinical response, which roughly equated to a 50% or greater response. We analysed LOS pressure within the first four weeks of treatment as this was assessed in all six of the selected studies.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-11-04 00:55:14 -0500" MODIFIED_BY="[Empty name]">
<P>Both the number of studies and the number of participants randomised to either treatment were small. A total of 239 achalasia participants were enrolled across the seven studies, with the largest study having 60 participants (<LINK REF="STD-Zhu-2009" TYPE="STUDY">Zhu 2009</LINK>); 122 participants were randomised to undergo PD and 117 to receive BTX. One RCT that involved 80 participants was not included as the only information that was available was from the abstract of the paper (<LINK REF="STD-Zhou-2012" TYPE="STUDY">Zhou 2012</LINK>). The outcomes reported in the abstract are in keeping with the result of this meta-analysis and allowing for the possibility of a high risk of bias, the 12 month clinical remission rates in this study were greater for PD than BTX, 73.2% and 61.5% respectively.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-11-04 00:57:38 -0500" MODIFIED_BY="[Empty name]">
<P>The overall methodological quality of these studies was good although the risk of bias is high (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Only one of the included studies was double blind (<LINK REF="STD-Bansal-2003" TYPE="STUDY">Bansal 2003</LINK>). Because of the nature of the interventions in the included studies blinding was not always possible; therefore these studies are open to the possibility of bias.</P>
<P>The overall clinical characteristics of the participants in both treatment groups in the studies included in the meta-analysis were similar. However, in the study by <LINK REF="STD-Mikaeli-2001" TYPE="STUDY">Mikaeli 2001</LINK> the BTX group were slightly older. Two patients who received BTX had previously had an unsuccessful PD (<LINK REF="STD-Ghoshal-2001" TYPE="STUDY">Ghoshal 2001</LINK>). Of the 239 participants only 11 were excluded from the post-treatment analysis; five of these were from the same study (<LINK REF="STD-Vaezi-1999" TYPE="STUDY">Vaezi 1999</LINK>).</P>
<P>Despite the small number of studies and participants, four of the studies that were identified by the search were excluded (<LINK REF="STD-Gaudric-1996" TYPE="STUDY">Gaudric 1996</LINK>; <LINK REF="STD-Nebendahl-1998" TYPE="STUDY">Nebendahl 1998</LINK>; <LINK REF="STD-des-Varannes-1999" TYPE="STUDY">des Varannes 1999</LINK>; <LINK REF="STD-Linghu-2013" TYPE="STUDY">Linghu 2013</LINK>) as they were only published as meeting abstracts and further information regarding the exact nature of the treatments and methodological quality, in particular the method of randomisation and the baseline comparability of the treatment groups, was not available. A further study was excluded as only the information in the paper's abstract was available (<LINK REF="STD-Zhou-2012" TYPE="STUDY">Zhou 2012</LINK>).</P>
<P>In summary, the results of this review suggest that PD has a better long-term efficacy. These studies suggest little difference in the response rates to initial treatment, however at 12 months the remission rate with PD was approximately twice that of BTX. No serious adverse outcomes occurred in participants receiving BTX. PD was complicated by perforation in three cases.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-11-04 01:14:06 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-11-04 01:14:06 -0500" MODIFIED_BY="[Empty name]">
<P>Existing randomised controlled trials in this area measure multiple interventions and outcomes, making comparisons difficult for clinicians. Pneumatic dilation (PD) appears to be associated with better long-term outcomes and reduced re-intervention rates when compared to botulinum toxin (BTX) injection. However, oesophageal perforation remains a risk with balloon dilatation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Large blinded randomised controlled trials with comparable treatment protocols and outcome assessment criteria are lacking.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-11-04 01:14:26 -0500" MODIFIED_BY="[Empty name]">
<P>We thank the Cochrane Upper Gastrointestinal and Pancreatic Disease Review Group.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-11-04 01:15:41 -0500" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-11-04 01:15:29 -0500" MODIFIED_BY="[Empty name]">
<P>Leyden J: protocol development, eligibility and quality assessment, data extraction and analysis, drafting of final review.</P>
<P>Moss A: protocol development, eligibility and quality assessment, data extraction and analysis, drafting of final review.</P>
<P>MacMathuna P: clinical and scientific advice, assessment of eligibility and quality, drafting of final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-04 01:47:37 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-11-04 01:42:34 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-11-04 01:36:47 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Annese-1996" NAME="Annese 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;DA - 19970102&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Annese V, Basciani M, Perri F, Lombardi G, Frusciante V, Simone P, et al</AU>
<TI>Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>111</VL>
<NO>6</NO>
<PG>1418-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bansal-2003" NAME="Bansal 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;DA - 20030218&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bansal R, Nostrant TT, Scheiman JM, Koshy S, Barnett JL, Elta GH, et al</AU>
<TI>Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>3</NO>
<PG>209-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="311"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghoshal-2001" NAME="Ghoshal 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;DA - 20020228&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghoshal UC, Chaudhuri S, Pal BB, Dhar K, Ray G, Banerjee PK</AU>
<TI>Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>3-4</NO>
<PG>227-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mikaeli-2001" NAME="Mikaeli 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;DA - 20010912&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mikaeli J, Fazel A, Montazeri G, Yaghoobi M, Malekzadeh R</AU>
<TI>Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>9</NO>
<PG>1389-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="312"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muehldorfer-1999" NAME="Muehldorfer 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;DA - 19991116&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muehldorfer SM, Schneider TH, Hochberger J, Martus P, Hahn EG, Ell C</AU>
<TI>Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation</TI>
<SO>Endoscopy</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>7</NO>
<PG>517-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="313"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaezi-1999" MODIFIED="2014-11-04 01:36:47 -0500" MODIFIED_BY="[Empty name]" NAME="Vaezi 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-11-04 01:36:47 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19990514&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:36:47 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaezi MF, Richter JE, Wilcox CM, Schroeder PL, Birgisson S, Slaughter RL, et al</AU>
<TI>Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>2</NO>
<PG>231-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2009" MODIFIED="2014-08-21 14:30:22 -0400" MODIFIED_BY="[Empty name]" NAME="Zhu 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-08-21 14:30:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu Q, Liu J, Yang C</AU>
<TI>Clinical study on combined therapy of botulinum toxin injection and small balloon dilation in patients with esophageal achalasia</TI>
<SO>Digestive Surgery</SO>
<YR>2009</YR>
<VL>26</VL>
<PG>493-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-11-04 01:42:34 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allescher-2001" MODIFIED="2014-07-07 17:50:14 -0400" MODIFIED_BY="[Empty name]" NAME="Allescher 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-07-07 17:50:14 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20011212&lt;/p&gt;" NOTES_MODIFIED="2014-07-07 17:50:14 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allescher HD, Storr M, Seige M, Gonzales-Donoso R, Ott R, Born P, et al</AU>
<TI>Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up</TI>
<SO>Endoscopy</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>12</NO>
<PG>1007-17</PG>
<IDENTIFIERS MODIFIED="2014-07-07 17:50:14 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-07 17:50:14 -0400" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bansal-1996" MODIFIED="2014-11-04 01:37:33 -0500" MODIFIED_BY="[Empty name]" NAME="Bansal 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-11-04 01:37:33 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:37:33 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bansal R, Koshy S, Scheiman JM, Barnett JL, Nostrant TT</AU>
<TI>Interim analysis of a randomized trial of Witzel pneumatic dilation vs intrasphincteric injection of botulinum toxin (Botox) for achalasia</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>4</NO>
<PG>A56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="279"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-des-Varannes-1999" MODIFIED="2014-11-04 01:38:04 -0500" MODIFIED_BY="[Empty name]" NAME="des Varannes 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-11-04 01:38:04 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:38:04 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>des Varannes SB, Lemiere S, Guillemot JF, Ducrotte P, Zerbib F, Rolachon A, et al</AU>
<TI>Botulinum toxin versus pneumatic dilatation in achalasia: Results of a multicentre controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<NO>4</NO>
<PG>G0557</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="191"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaudric-1996" MODIFIED="2014-11-04 01:38:22 -0500" MODIFIED_BY="[Empty name]" NAME="Gaudric 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-11-04 01:38:22 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:38:22 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gaudric M, Guimbaud R, Chaussade S, Palazzo L, Quartier G, Samama J, et al</AU>
<TI>Pneumatic dilatation (PD) versus intrasphincteric botulinum toxin (BT) in the treatment of achalasia: Preliminary results of a controlled study</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>4</NO>
<PG>A667</PG>
<IDENTIFIERS MODIFIED="2014-07-07 17:45:28 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-07 17:45:28 -0400" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="284"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2012" MODIFIED="2014-11-04 01:39:34 -0500" MODIFIED_BY="[Empty name]" NAME="Jung 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-04 01:39:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung HE, Lee JS, Kim JO, Hong SJ, Lee TH, Kim HG, et al</AU>
<TI>The long-term outcome in patients with primary achalasia according to the balloon dilatation or intrasphincteric botulinum toxin injection</TI>
<SO>Neurogastroenterology and Motility</SO>
<YR>2012</YR>
<VL>24 Suppl 2</VL>
<PG>97</PG>
<IDENTIFIERS MODIFIED="2014-08-21 14:30:35 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-06-23 17:58:07 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linghu-2013" MODIFIED="2014-11-04 01:41:06 -0500" MODIFIED_BY="[Empty name]" NAME="Linghu 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-11-04 01:41:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linghu E, Li H</AU>
<TI>Randomized study comparing peroral endoscopic myotomy, botulinum toxin injection and balloon dilation for achalasia: one-year follow-up. Program and abstracts of the American College of Gastroenterology 2013 Annual Scientific Meeting; October 11-16, 2013; San Diego, California</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2013</YR>
<VL>108</VL>
<PG>Abstract 28</PG>
<IDENTIFIERS MODIFIED="2014-07-07 18:01:31 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malekzadeh-2000" MODIFIED="2014-11-04 01:41:29 -0500" MODIFIED_BY="[Empty name]" NAME="Malekzadeh 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-11-04 01:41:29 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:41:29 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malekzadeh R, Milkaeli J, Fazel A, Montazeri G, Yaghoobi M, Khatibian M, et al</AU>
<TI>A randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for treatment of achalasia</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2000</YR>
<VL>51</VL>
<NO>4</NO>
<PG>4468</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muehldorfer-1998" MODIFIED="2014-11-04 01:41:44 -0500" MODIFIED_BY="[Empty name]" NAME="Muehldorfer 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-11-04 01:41:44 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:41:44 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muehldorfer SM, Schneider T, Hochberger J, Hahn EG, Ell C</AU>
<TI>Intrasphincteric injection of botulinum toxin A versus balloon dilation in patients with achalasia. A randomized prospective comparative trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>4</NO>
<PG>199</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="225"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nebendahl-1998" MODIFIED="2014-11-04 01:42:03 -0500" MODIFIED_BY="[Empty name]" NAME="Nebendahl 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-11-04 01:42:03 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal&lt;/p&gt;" NOTES_MODIFIED="2014-11-04 01:42:03 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nebendahl JC, Brand B, von Schrenck T, Matsui U, Thonke F, Bohnacker S, et al</AU>
<TI>Prospective randomised comparison of dilation (high compliance balloon) vs. botulinum toxin injection (BTX) in esophageal achalasia</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>4</NO>
<PG>G0985</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="218"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2012" MODIFIED="2014-11-04 01:42:34 -0500" MODIFIED_BY="[Empty name]" NAME="Zhou 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-04 01:42:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou H, Dai Y, Lu L, Luo S, Qian Y, Wan X</AU>
<TI>Endoscopic water-filled balloon dilatation and botulinum toxin injection for treatment of achalasia: A comparison of clinical effectiveness</TI>
<SO>Academic Journal of Second Military Medical University</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1000-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-11-04 01:47:37 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-11-04 01:47:37 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Annese-1998" MODIFIED="2014-11-04 01:44:10 -0500" MODIFIED_BY="[Empty name]" NAME="Annese 1998" TYPE="JOURNAL_ARTICLE">
<AU>Annese V, Basciani M, Borrelli O, Leandro G, Simone P, Andriulli A</AU>
<TI>Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>1540-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bassotti-1999" NAME="Bassotti 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bassotti G, Annese V</AU>
<TI>Pharmacological options in achalasia</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>1391-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cuilliere-1997" MODIFIED="2014-11-04 01:45:05 -0500" MODIFIED_BY="[Empty name]" NAME="Cuilliere 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cuilliere C, Ducrotte P, Zerbib F, et al</AU>
<TI>Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin</TI>
<SO>Gut</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eckardt-1997" NAME="Eckardt 1997" TYPE="JOURNAL_ARTICLE">
<AU>Eckardt VF, Kohne U, Junginger T, Westermeier T</AU>
<TI>Risk factors for diagnostic delay in achalasia</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>3</NO>
<PG>580-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frantzides-2004" NAME="Frantzides 2004" TYPE="JOURNAL_ARTICLE">
<AU>Frantzides CT, Moore RE, Carlson MA, et al</AU>
<TI>Minimally invasive surgery for achalasia: a 10-year experience</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2014-11-04 01:45:52 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008. Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1992" NAME="Howard 1992" TYPE="JOURNAL_ARTICLE">
<AU>Howard PJ. Maher L, Pryde A, et al</AU>
<TI>Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edingburgh</TI>
<SO>Gut</SO>
<YR>1992</YR>
<VL>33</VL>
<PG>1011-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imperiale-2000" NAME="Imperiale 2000" TYPE="JOURNAL_ARTICLE">
<AU>Imperiale TF, O'Connor JB, Vaezi MF, Richter JE</AU>
<TI>A cost-minimization analysis of alternative treatment strategies for achalasia</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>10</NO>
<PG>2737-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inoue-2010" MODIFIED="2014-08-21 14:31:28 -0400" MODIFIED_BY="[Empty name]" NAME="Inoue 2010" TYPE="JOURNAL_ARTICLE">
<AU>Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, et al</AU>
<TI>Peroral endoscopic myotomy (POEM) for esophageal achalasia</TI>
<SO>Endoscopy</SO>
<YR>2010</YR>
<VL>42</VL>
<PG>265-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kadakia-2001" NAME="Kadakia 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kadakia SC, Wong RK</AU>
<TI>Pneumatic balloon dilation for esophageal achalasia</TI>
<SO>Gastrointestinal Endoscopy Clinics of North America</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>2</NO>
<PG>325-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katz-1998" NAME="Katz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Katz PO, Gilbert J, Costell D</AU>
<TI>Pneumatic dilation is effective long-term treatment for achalasia</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>1973-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolbasnik-1999" NAME="Kolbasnik 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kolbasnik J, Waterfall WE, Fachnie B, Chen Y, Tougas G</AU>
<TI>Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>12</NO>
<PG>3434-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayberry-1987" NAME="Mayberry 1987" TYPE="JOURNAL_ARTICLE">
<AU>Mayberry JF, Atkinson M</AU>
<TI>Variations in the prevalence of achalasia in Great Britain and Ireland: an epidemiological study based on hospital admissions</TI>
<SO>The Quarterly Journal of Medicine</SO>
<YR>1987</YR>
<VL>62</VL>
<PG>67-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasricha-1994" NAME="Pasricha 1994" TYPE="JOURNAL_ARTICLE">
<AU>Pasricha PJ, Ravich WJ, Hendric TR, Kalloo AN</AU>
<TI>Treatment of achalasia with intrasphincteric injection of botulinum toxin: a pilot trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>590-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasricha-1995" NAME="Pasricha 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN</AU>
<TI>Botulinum toxin for the treatment of achalasia</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>322</VL>
<PG>774-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasricha-2007" MODIFIED="2014-11-04 01:47:37 -0500" MODIFIED_BY="[Empty name]" NAME="Pasricha 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pasricha PJ, Hawari R, Ahmed I, Chen J, Cotton PB, Hawes RH, et al</AU>
<TI>Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia</TI>
<SO>Endoscopy</SO>
<YR>2007</YR>
<VL>39</VL>
<PG>761-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1989" NAME="Reynolds 1989" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds, JC, Parkman, HP</AU>
<TI>Achalasia</TI>
<SO>Gastroenterology Clinics of North America</SO>
<YR>1989</YR>
<VL>18</VL>
<PG>223</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Urbach-2001" NAME="Urbach 2001" TYPE="JOURNAL_ARTICLE">
<AU>Urbach DR, Hansen PD, Khajanchee YS, Swanstrom LL</AU>
<TI>A decision analysis of the optimal initial approach to achalasia: laparoscopic Heller myotomy with partial fundoplication, thoracoscopic Heller myotomy, pneumatic dilatation, or botulinum toxin injection</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>2</NO>
<PG>192-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vela-2004" NAME="Vela 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vela MF, Richter JE, Wachsberger D, Connor J, Rice TW</AU>
<TI>Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>6</NO>
<PG>1029-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Renteln-2013" MODIFIED="2014-08-21 14:32:00 -0400" MODIFIED_BY="[Empty name]" NAME="Von Renteln 2013" TYPE="JOURNAL_ARTICLE">
<AU>Von Renteln D, Fuchs KH, Fockens P, Bauerfeind P, Vassiliou MC, Werner YB, et al</AU>
<TI>Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study</TI>
<SO>Gastroenterology</SO>
<YR>2013</YR>
<VL>145</VL>
<NO>2</NO>
<PG>309-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wen-2004" MODIFIED="2011-07-14 10:05:35 -0400" MODIFIED_BY="Karin Dearness" NAME="Wen 2004" TYPE="COCHRANE_REVIEW">
<AU>Wen ZH, Gardener E, Wang YP</AU>
<TI>Nitrates for achalasia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2011-07-14 10:05:35 -0400" MODIFIED_BY="Karin Dearness">
<IDENTIFIER MODIFIED="2011-07-14 10:05:35 -0400" MODIFIED_BY="Karin Dearness" TYPE="DOI" VALUE="10.1002/14651858.CD002299.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-11-04 01:34:11 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-11-04 01:31:59 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-11-04 01:18:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Annese-1996">
<CHAR_METHODS MODIFIED="2014-11-04 01:17:11 -0500" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Method of randomisation was not stated<BR/>Initially BTX versus placebo saline injection. All placebos relapsed and treated by PD<BR/>BTX relapsers were retreated<BR/>Remission - symptom score &#8804; 2<BR/>Exclusion criteria: &lt; 18 yrs, previous PD or myotomy, sigmoid shaped oesophagus</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:17:19 -0500" MODIFIED_BY="[Empty name]">
<P>16 treatment naive adult participants<BR/>Baseline characteristics of both treatment groups were similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:17:41 -0500" MODIFIED_BY="[Empty name]">
<P>8 participants received 100 U BTX and 8 participants underwent PD<BR/>PD: day 1 - Rigiflex 30 mm, day 2 and 3 - 35 mm balloon</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:18:34 -0500" MODIFIED_BY="[Empty name]">
<P>Clinical assessment using mean symptom score - dysphagia, chest pain and regurgitation; each scored 0 to 3<BR/>Mean LOS pressure (mm Hg)<BR/>Barium retention studies (mean % retained at 10 min)<BR/>Outcomes assessed at 1, 6, 12 months<BR/>Remission defined as a symptom score &#8804; 2</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-04 01:18:51 -0500" MODIFIED_BY="[Empty name]">
<P>No complications reported<BR/>All patients were assessed at 6 months; 6 participants were lost to follow up at 12 months<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-04 01:21:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bansal-2003">
<CHAR_METHODS MODIFIED="2014-11-04 01:20:35 -0500" MODIFIED_BY="[Empty name]">
<P>Double blind RCT<BR/>Method of randomisation was not stated<BR/>Crossover to other treatment if failed treatment at any time<BR/>Exclusion criteria: previous treatment, &lt; 18 yrs, poor surgical candidates<BR/>Remission - decrease in symptom grade &#8805; 1<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:20:39 -0500" MODIFIED_BY="[Empty name]">
<P>34 treatment naive adults<BR/>Baseline characteristics of both treatment groups were similar<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:21:00 -0500" MODIFIED_BY="[Empty name]">
<P>BTX 80 U 4 quadrants<BR/>Witzel 40 mm balloon - 180 to 300 mm Hg x 3 min<BR/>Sham injection or dilatation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:21:43 -0500" MODIFIED_BY="[Empty name]">
<P>Mean symptom score - dysphagia, chest pain, regurgitation (0 to 9)<BR/>Dysphagia score (0 to 21)<BR/>Dysphagia severity (0 to 10)<BR/>Pain severity (0 to 10)<BR/>Global assessment (0 to 10, graded 0, 1, 2, 3)<BR/>Weight gain (%)<BR/>Mean LOS pressure (mm Hg)at 3 weeks, 3 months, and 12 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-04 01:21:59 -0500" MODIFIED_BY="[Empty name]">
<P>2 perforations in PD group<BR/>2 lost to follow up<BR/>Low bias<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-04 01:23:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghoshal-2001">
<CHAR_METHODS MODIFIED="2014-11-04 01:23:00 -0500" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Method of randomisation - computer generated random numbers<BR/>Non-responders and relapsers retreated with PD<BR/>Remission - dysphagia score 0 or 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:22:53 -0500" MODIFIED_BY="[Empty name]">
<P>17 participants<BR/>2 BTX group had previous PD<BR/>Baseline characteristics of both treatment groups were similar<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:23:19 -0500" MODIFIED_BY="[Empty name]">
<P>BTX 60 to 80 units<BR/>Rigiflex 30 mm - 1 min 10 to 15 psi</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:23:52 -0500" MODIFIED_BY="[Empty name]">
<P>Dysphagia (0 to 3), chest pain (Yes or No), regurgitation (Yes or No)<BR/>Symptoms assessed at 1 week, 3 to 6 monthly<BR/>Mean LOS pressure at 1 week<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-15 18:06:45 -0400" MODIFIED_BY="[Empty name]">
<P>No complications<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-04 01:25:56 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mikaeli-2001">
<CHAR_METHODS MODIFIED="2014-11-04 01:24:45 -0500" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Method of randomisation - computer generated random numbers<BR/>Repeat treatment for non-response and relapse (same BTX dose or 35 mm PD)<BR/>Remission - &gt; 50% improvement in symptom score<BR/>Exclusion criteria: &lt; 40 yrs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:25:56 -0500" MODIFIED_BY="[Empty name]">
<P>40 treatment naive participants (&gt; 40 yr old)<BR/>BTX group older</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:25:17 -0500" MODIFIED_BY="[Empty name]">
<P>BTX 200 (80) U 4 quadrants<BR/>Rigiflex 30 mm - 10 psi x 30 sec</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:25:23 -0500" MODIFIED_BY="[Empty name]">
<P>Mean symptom (0 to 15) 1, 6, 12 months<BR/>Mean LOS pressure at 1 month<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-04 01:25:34 -0500" MODIFIED_BY="[Empty name]">
<P>No complication<BR/>1 lost to follow up<BR/>High risk of bias as not double blind</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-04 01:28:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muehldorfer-1999">
<CHAR_METHODS MODIFIED="2014-11-04 01:27:03 -0500" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Method of randomisation not stated<BR/>Exclusion criteria: secondary achalasia, dysphagia score &lt; 10/20, previous gastro-oesophageal surgery<BR/>Remission - &#8805; 50% reduction in symptoms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:27:08 -0500" MODIFIED_BY="[Empty name]">
<P>24 participants - 15 had previously undergone PD<BR/>Baseline characteristics of both treatment groups were similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:27:30 -0500" MODIFIED_BY="[Empty name]">
<P>BTX 80 Units<BR/>40 mm PD - up to 300 mm Hg x 3 min day 1 and 3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:27:56 -0500" MODIFIED_BY="[Empty name]">
<P>Median score (0 to 20) for 4 symptoms - dysphagia, regurgitation, chest pain, and heartburn at 1 week, 1 month and 6 monthly for 30 months<BR/>Mean LOS pressure post-treatment in 16 patients<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-04 01:28:02 -0500" MODIFIED_BY="[Empty name]">
<P>No complications</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-04 01:29:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaezi-1999">
<CHAR_METHODS MODIFIED="2014-11-04 01:28:49 -0500" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Method of randomisation - computer generated random numbers<BR/>Retreated if no response at 1 month (35 mm PD balloon)<BR/>Exclusion criteria: previous treatment, &lt; 18 yrs, neuromuscular disorder, NYHA grade III or IV<BR/>Remission - &gt; 50% improvement in symptoms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:28:58 -0500" MODIFIED_BY="[Empty name]">
<P>47 treatment naive participants<BR/>Baseline characteristics of both treatment groups were similar<BR/>5 participants were excluded from the analysis - 2 BTX group and 3 PD group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:29:11 -0500" MODIFIED_BY="[Empty name]">
<P>BTX 100 U<BR/>Rigiflex 30 mm - 9 to 15 psi x 1 minute</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:29:25 -0500" MODIFIED_BY="[Empty name]">
<P>Median symptom score (0 to 15)<BR/>Symptoms assessed at 1, 3, 6, 9, 12 months<BR/>Median LOS pressure at 1 month<BR/>Barium retention - height and width 1, 6, 12 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-04 01:29:33 -0500" MODIFIED_BY="[Empty name]">
<P>1 perforation in PD group - excluded from analysis<BR/>4 lost to follow up - excluded from analysis<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-04 01:31:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2009">
<CHAR_METHODS MODIFIED="2014-06-15 16:44:13 -0400" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-04 01:30:21 -0500" MODIFIED_BY="[Empty name]">
<P>90 participants divided into three groups. Adults &gt; 40 yrs. Treatment naive</P>
<P>Three treatment groups - A) 100 U BTX, B) PD with 30 mm Rigifex balloon, C) PD followed by BTX injection 15 days later</P>
<P>Baseline characteristics similar in the two relevant groups</P>
<P>Outcomes based on single treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-04 01:30:30 -0500" MODIFIED_BY="[Empty name]">
<P>Three treatment groups - A) 100 U BTX, B) PD with 30 mm Rigifex balloon, C) PD followed by BTX injection 15 days later</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-04 01:31:08 -0500" MODIFIED_BY="[Empty name]">
<P>Clinical assessment (mean symptoms score based on dysphagia for solids and liquids, active and passive regurgitation. and chest pain; each scored 0 to 3) and mean lower oesophageal sphincter pressure were assessed after therapy at 1 month, 6 months, 12 months, 18 months, and 24 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-04 01:31:20 -0500" MODIFIED_BY="[Empty name]">
<P>No major complications reported - significant bleeding requiring hospitalisation, oesophageal perforation, and aspiration</P>
<P>3 lost to follow up (one from BTX and 2 from PD group) - excluded from analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-11-04 01:34:11 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allescher-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:11 -0500" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bansal-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:20 -0500" MODIFIED_BY="[Empty name]">
<P>Duplicate - meeting abstract. Full paper later published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-des-Varannes-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:23 -0500" MODIFIED_BY="[Empty name]">
<P>Meeting abstract - unable to contact author for more information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:25 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaudric-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:25 -0500" MODIFIED_BY="[Empty name]">
<P>Meeting abstract - unable to contact author for more information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-15 16:43:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jung-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-15 16:43:38 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT - meeting abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linghu-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:29 -0500" MODIFIED_BY="[Empty name]">
<P>Meeting abstract - unable to contact author for more information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malekzadeh-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:40 -0500" MODIFIED_BY="[Empty name]">
<P>Duplicate - meeting abstract. Full paper later published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muehldorfer-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:46 -0500" MODIFIED_BY="[Empty name]">
<P>Duplicate - meeting abstract. Full paper later published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:32:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nebendahl-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:32:48 -0500" MODIFIED_BY="[Empty name]">
<P>Meeting abstract - unable to contact author for more information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-04 01:34:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-04 01:34:11 -0500" MODIFIED_BY="[Empty name]">
<P>RCT published in Chinese</P>
<P>Unable to contact author to obtain more information</P>
<P>Key points from abstract:</P>
<UL>
<LI>80 patients randomly assigned to PD or BTX</LI>
<LI>clinical symptoms and oesophageal kinematics of patients were evaluated before and 1 week, 1 month, and clinical outcomes were recorded during a follow up of 24 months</LI>
<LI>clinical symptom scores and the lower oesophageal sphincter pressure were significantly improved in both treatment groups at 1 week and 1 month after therapy (P &lt; 0.01)</LI>
<LI>at 12 months, the clinical remission rates in PD group and BTX group were 73.2% and 61.5%, respectively</LI>
</UL>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-11-04 01:31:51 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-11-04 01:31:32 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:19:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annese-1996">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 21:42:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:24:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION>
<P>Method of randomisation - computer generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:26:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION>
<P>Computer generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 21:55:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-04 18:23:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION>
<P>Method of randomisation - computer generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:31:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION>
<P>Computer generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-11-04 01:31:45 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:19:19 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Annese-1996">
<DESCRIPTION>
<P>Initial randomisation and therapy was double blind - BTX or placebo saline injection. The placebo group then had three PD sessions as they all failed to respond. This aspect of the study was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-21 14:37:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION>
<P>Allocation concealment and sham procedures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:24:06 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION>
<P>Patients were unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:26:12 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION>
<P>Patients were unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:28:06 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION>
<P>Patients were unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:29:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION>
<P>Patients were unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-04 01:31:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION>
<P>Allocation concealed, randomisation occurred after enrolment. Patients blinded to therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-11-04 01:31:46 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-04 01:19:25 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Annese-1996">
<DESCRIPTION>
<P>Initial randomisation and therapy was double blind - BTX or placebo saline injection. The placebo group then had three PD sessions as they all failed to respond. This aspect of the study was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-21 14:37:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION>
<P>Double blinding to initial therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-04 01:24:11 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-04 01:26:15 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-04 01:28:14 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-04 01:29:45 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-04 01:31:46 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION>
<P>Patients and assessors blinded to therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-11-04 01:31:48 -0500" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-04 01:19:32 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Annese-1996">
<DESCRIPTION>
<P>Initial randomisation and therapy was double blind - BTX or placebo saline injection. The placebo group then had three PD sessions as they all failed to respond. This aspect of the study was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-08-21 14:37:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION>
<P>Double blinding to initial therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-04 01:24:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-07 17:41:16 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-04 01:28:17 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-04 01:29:47 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION>
<P>Patients were unblinded. Nature of therapies administered did not allow blinding of endoscopists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-04 01:31:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION>
<P>Patients and assessors blinded to therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-11-04 01:31:51 -0500" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-07 17:40:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annese-1996">
<DESCRIPTION>
<P>It is unclear whether the assessors were blinded to the therapies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-04 18:39:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION>
<P>Assessors blinded to therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-07 17:36:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION>
<P>It is unclear whether the assessors were blinded to the therapies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-04 19:06:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION>
<P>Clinical assessor was aware of the treatment received by the patient </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-07 17:36:43 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION>
<P>It is unclear whether the assessors were blinded to the therapies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-07 17:29:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION>
<P>It is unclear whether the assessors were blinded to the therapies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-04 01:31:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION>
<P>Patients and assessors blinded to therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-07-07 17:39:13 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-15 17:40:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annese-1996">
<DESCRIPTION>
<P>Low attrition bias at 1 and 6 months but high at 12 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-04 18:40:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION>
<P>Two lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-07 17:17:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-04 19:11:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION>
<P>One participant lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-07 17:39:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION>
<P>No participants lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-07 17:27:51 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION>
<P>5 patients not included in analysis, 4 in the PD group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-15 16:54:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION>
<P>3 lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-06-23 17:15:58 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 17:39:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annese-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:29:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:29:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:28:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:28:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:27:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 16:53:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-06-23 17:15:58 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:26:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annese-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:27:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bansal-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:29:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghoshal-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:29:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mikaeli-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:28:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muehldorfer-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 18:27:26 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaezi-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-15 16:53:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-11-04 01:35:10 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-11-04 01:35:10 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Studies meeting selection criteria but excluded from the meta-analysis</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>methods</P>
</TH>
<TH>
<P>Remission 1 month</P>
</TH>
<TH>
<P>Remission 6 months</P>
</TH>
<TH>
<P>Remission 12 months</P>
</TH>
<TH>
<P>Mean LOS pressure</P>
</TH>
<TH>
<P>Complications</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Annese-1996" TYPE="STUDY">Annese 1996</LINK>
</P>
</TD>
<TD>
<P>8 participants 100 U BTX and 8 participants PD<BR/>PD: day 1 - Rigiflex 30 mm. Day 2 and 3 - 35 mm balloon<BR/>BTX relapsers retreated</P>
</TD>
<TD>
<P>PD 8/8<BR/>BTX 8/8</P>
</TD>
<TD>
<P>PD 8/8<BR/>BTX 6/8<BR/>
</P>
</TD>
<TD>
<P>PD 8/8<BR/>BTX 1/8</P>
</TD>
<TD>
<P>PD -72%<BR/>BTX -44%</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Muehldorfer-1999" TYPE="STUDY">Muehldorfer 1999</LINK>
</P>
</TD>
<TD>
<P>12 participants 80 U BTX and 12 PD 40m day 1 and 3<BR/>BTX repeated at 1 week in 4 non-responders</P>
</TD>
<TD>
<P>PD 10/12<BR/>BTX 9/12</P>
</TD>
<TD>
<P>PD 9/12<BR/>BTX 6/12</P>
</TD>
<TD>
<P>PD 8/12<BR/>BTX 3/12</P>
</TD>
<TD>
<P>PD -50%<BR/>BTX -44%<BR/>
</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-11-04 01:48:42 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-11-04 01:48:42 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Pneumatic dilation versus botulinum toxin injection</NAME>
<DICH_OUTCOME CHI2="3.8997262661723373" CI_END="1.2668571596674436" CI_START="0.9696976685462311" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1083629523358405" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.10272765019097516" LOG_CI_START="-0.013363648567142079" LOG_EFFECT_SIZE="0.04468200081191656" METHOD="MH" MODIFIED="2014-07-15 16:54:17 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41974664012916896" P_Q="1.0" P_Z="0.13136823719776192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="1.508728273098462">
<NAME>Initial remission</NAME>
<GROUP_LABEL_1>PD</GROUP_LABEL_1>
<GROUP_LABEL_2>BTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7071070312668044" CI_START="0.9289012657006293" EFFECT_SIZE="1.2592592592592593" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.23226075112723985" LOG_CI_START="-0.03203044536070422" LOG_EFFECT_SIZE="0.10011515288326783" ORDER="22242" O_E="0.0" SE="0.15524595707954034" STUDY_ID="STD-Bansal-2003" TOTAL_1="18" TOTAL_2="16" VAR="0.02410130718954248" WEIGHT="17.35460304547267"/>
<DICH_DATA CI_END="1.4391023792587703" CI_START="0.6053155937104273" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.15809169120244568" LOG_CI_START="-0.21801813795733213" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="22243" O_E="0.0" SE="0.22092877542213413" STUDY_ID="STD-Ghoshal-2001" TOTAL_1="10" TOTAL_2="7" VAR="0.048809523809523775" WEIGHT="9.641446136373705"/>
<DICH_DATA CI_END="1.9664352969746062" CI_START="0.9635722106481454" EFFECT_SIZE="1.3765182186234817" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.2936796610792586" LOG_CI_START="-0.01611573351407984" LOG_EFFECT_SIZE="0.13878196378258936" ORDER="22244" O_E="0.0" SE="0.1819753482960624" STUDY_ID="STD-Mikaeli-2001" TOTAL_1="19" TOTAL_2="20" VAR="0.033115027387473225" WEIGHT="17.30103945582615"/>
<DICH_DATA CI_END="1.4137160630097458" CI_START="0.6552986658634391" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.15036219259345665" LOG_CI_START="-0.18356071623238007" LOG_EFFECT_SIZE="-0.016599261819461704" ORDER="22245" O_E="0.0" SE="0.19614796958935354" STUDY_ID="STD-Vaezi-1999" TOTAL_1="20" TOTAL_2="22" VAR="0.038474025974025966" WEIGHT="20.813280548362282"/>
<DICH_DATA CI_END="1.216323344093427" CI_START="0.8819234513929199" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.08504904195034287" LOG_CI_START="-0.054569108836869065" LOG_EFFECT_SIZE="0.015239966556736905" MODIFIED="2014-06-16 17:48:09 -0400" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.08201239289340094" STUDY_ID="STD-Zhu-2009" TOTAL_1="28" TOTAL_2="29" VAR="0.00672603258810156" WEIGHT="34.8896308139652"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.29287453420552084" CI_END="0.13754787459686985" CI_START="-0.5126521863307958" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18755215586696294" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2014-07-15 16:54:35 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.961362971879024" P_Q="1.0" P_Z="0.25817509773895" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="1.1307149685517635">
<NAME>Mean oesophageal pressure within first four weeks</NAME>
<GROUP_LABEL_1>PD</GROUP_LABEL_1>
<GROUP_LABEL_2>BTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5384541430729073" CI_START="-0.8101521935632736" EFFECT_SIZE="-0.13584902524518322" ESTIMABLE="YES" MEAN_1="19.6" MEAN_2="20.0" ORDER="22246" SD_1="3.3" SD_2="2.3" SE="0.3440385505228197" STUDY_ID="STD-Bansal-2003" TOTAL_1="18" TOTAL_2="16" WEIGHT="23.244682569929793"/>
<CONT_DATA CI_END="0.5539709422207486" CI_START="-1.4051774785927411" EFFECT_SIZE="-0.42560326818599625" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="17.5" ORDER="22247" SD_1="4.5" SD_2="4.4" SE="0.4997919442058636" STUDY_ID="STD-Ghoshal-2001" TOTAL_1="10" TOTAL_2="7" WEIGHT="11.014361717052614"/>
<CONT_DATA CI_END="0.41935500368416534" CI_START="-0.8402986472846543" EFFECT_SIZE="-0.21047182180024446" ESTIMABLE="YES" MEAN_1="46.06" MEAN_2="48.2" ORDER="22248" SD_1="11.5" SD_2="8.24" SE="0.32134612189428147" STUDY_ID="STD-Mikaeli-2001" TOTAL_1="19" TOTAL_2="20" WEIGHT="26.643526823752666"/>
<CONT_DATA CI_END="0.3843180092270783" CI_START="-0.6555372834619726" EFFECT_SIZE="-0.13560963711744717" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="18.3" MODIFIED="2014-06-16 18:00:26 -0400" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="7.4" SD_2="5.6" SE="0.26527408179213924" STUDY_ID="STD-Zhu-2009" TOTAL_1="28" TOTAL_2="29" WEIGHT="39.09742888926492"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.678121382595318" CI_END="2.081100798963816" CI_START="1.189207592112683" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5731690532423845" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="29" I2="79.33483244385934" I2_Q="100.0" ID="CMP-001.03" LOG_CI_END="0.31829311595097587" LOG_CI_START="0.0752576731549311" LOG_EFFECT_SIZE="0.19677539455295348" METHOD="MH" MODIFIED="2014-07-15 17:32:07 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.007914532186313994" P_Q="0.0" P_Z="0.0015045842551638076" Q="1.5119799709485938E-31" RANDOM="NO" SCALE="16.169437542979793" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="56" WEIGHT="100.0" Z="3.1737978784526852">
<NAME>Remission at six months</NAME>
<GROUP_LABEL_1>PD</GROUP_LABEL_1>
<GROUP_LABEL_2>BTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PD</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.40483725549236" CI_START="0.8336135742722706" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9733512847717617" LOG_CI_START="-0.07903522208732336" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2014-07-15 17:05:38 -0400" MODIFIED_BY="[Empty name]" ORDER="22249" O_E="0.0" SE="0.6181770435262516" STUDY_ID="STD-Ghoshal-2001" TOTAL_1="10" TOTAL_2="7" VAR="0.3821428571428572" WEIGHT="8.15895089764976"/>
<DICH_DATA CI_END="6.594013377159993" CI_START="1.3174041532138532" EFFECT_SIZE="2.9473684210526314" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8191498238536729" LOG_CI_START="0.11971902825307003" LOG_EFFECT_SIZE="0.46943442605337143" ORDER="22250" O_E="0.0" SE="0.41084911157407056" STUDY_ID="STD-Mikaeli-2001" TOTAL_1="19" TOTAL_2="20" VAR="0.16879699248120306" WEIGHT="16.89321243551841"/>
<DICH_DATA CI_END="1.4580211421700011" CI_START="0.8755747591374059" EFFECT_SIZE="1.12987012987013" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.16376382155479186" LOG_CI_START="-0.057706766662518526" LOG_EFFECT_SIZE="0.05302852744613667" MODIFIED="2014-07-15 17:05:32 -0400" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.13009291981594065" STUDY_ID="STD-Zhu-2009" TOTAL_1="28" TOTAL_2="29" VAR="0.01692416778623676" WEIGHT="74.94783666683183"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.128340436602502" CI_END="2.611817831317141" CI_START="1.3540809876286812" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8805884367761372" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="27" I2="41.50154348981785" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.41694288255222367" LOG_CI_START="0.1316446402932792" LOG_EFFECT_SIZE="0.27429376142275147" METHOD="MH" MODIFIED="2014-07-20 16:21:08 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.16263729711115982" P_Q="1.0" P_Z="1.6408084648003178E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="72" WEIGHT="100.0" Z="3.7687290977745964">
<NAME>Remission at twelve months</NAME>
<GROUP_LABEL_1>PD</GROUP_LABEL_1>
<GROUP_LABEL_2>BTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PD</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.555646923456038" CI_START="1.2333387084500613" EFFECT_SIZE="2.3703703703703702" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.6585500575631852" LOG_CI_START="0.0910823620866145" LOG_EFFECT_SIZE="0.3748162098248998" ORDER="22251" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Bansal-2003" TOTAL_1="18" TOTAL_2="16" VAR="0.1111111111111111" WEIGHT="23.229784096648533"/>
<DICH_DATA CI_END="8.462783083207505" CI_START="0.7092820341703685" EFFECT_SIZE="2.45" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9275132092463703" LOG_CI_START="-0.14918104051730519" LOG_EFFECT_SIZE="0.3891660843645325" ORDER="22252" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Ghoshal-2001" TOTAL_1="10" TOTAL_2="7" VAR="0.39999999999999997" WEIGHT="8.603623739499458"/>
<DICH_DATA CI_END="10.83060795897294" CI_START="1.1367303204179748" EFFECT_SIZE="3.508771929824561" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0346528357404163" LOG_CI_START="0.055657444242563275" LOG_EFFECT_SIZE="0.5451551399914898" ORDER="22253" O_E="0.0" SE="0.5750667390711838" STUDY_ID="STD-Mikaeli-2001" TOTAL_1="19" TOTAL_2="20" VAR="0.33070175438596494" WEIGHT="10.688347953301248"/>
<DICH_DATA CI_END="1.9374138899367248" CI_START="0.8651223862164843" EFFECT_SIZE="1.2946428571428572" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.28722240900731383" LOG_CI_START="-0.06292244987772727" LOG_EFFECT_SIZE="0.1121499795647933" MODIFIED="2014-06-16 18:45:20 -0400" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.20567682335407808" STUDY_ID="STD-Zhu-2009" TOTAL_1="28" TOTAL_2="29" VAR="0.042302955665024636" WEIGHT="57.478244210550756"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-11-04 01:31:52 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-07-23 17:01:08 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUAAAAG8CAYAAACvwHzIAAAnRElEQVR42u2df4QV3+P/XyRJkkiS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-11-04 01:31:52 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-11-04 01:31:52 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWkAAAInCAIAAADVoz+YAAAc1klEQVR42u3dv44dxdbG4S0hIQIH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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-11-04 01:50:14 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-11-04 01:50:14 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-11-04 01:50:14 -0500" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-10 06:57:16 -0400" MODIFIED_BY="Cathy Bennett">
<P>1. randomized controlled trial.pt.</P>
<P>2. controlled clinical trial.pt.</P>
<P>3. randomized.ab.</P>
<P>4. placebo.ab.</P>
<P>5. drug therapy.fs.</P>
<P>6. randomly.ab.</P>
<P>7. trial.ab.</P>
<P>8. groups.ab.</P>
<P>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
<P>10. humans.sh.</P>
<P>11. 9 and 10</P>
<P>12. exp esophageal achalasia/</P>
<P>13.(esophageal adj2 achalasia).tw.</P>
<P>14. achalasi$.tw.</P>
<P>15. or/12-14</P>
<P>16. exp botulinum toxins/</P>
<P>17. botox.tw.</P>
<P>18. botulinum$.tw.</P>
<P>19. or/16-18</P>
<P>20. exp balloon dilatation/</P>
<P>21. angioplasty.tw.</P>
<P>22. (balloon adj5 dilat$).tw.</P>
<P>23. (pneumatic adj5 balloon).tw.</P>
<P>24. or/20-23</P>
<P>25. 11 and 15 and 19 and 24</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Five studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Seven studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Nine full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<OUT TEXT="&lt;p&gt;Two full-text articles excluded - one was not a RCT and one was a RCT but only published in Chinese&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>